Avid Bioservices Inc. (CDMO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Avid Bioservices Inc. (CDMO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

12.43

0.00 (0.00%)

At close: Jan 14, 2025, 3:59 PM

12.42

-0.04%

After-hours Jan 14, 2025, 04:01 PM EST

undefined% (undefined)

Bid	12.38
Market Cap	794.74M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.41
PE Ratio (ttm)	-5.16
Forward PE	n/a
Analyst	Hold

Ask	12.45
Volume	1,350,391
Avg. Volume (20D)	1,964,775
Open	12.42
Previous Close	12.43
Day's Range	12.42 - 12.44
52-Week Range	5.90 - 12.48
Beta	undefined

About CDMO

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk p...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 4, 1994

Employees 371

Stock Exchange NASDAQ

Ticker Symbol CDMO

Website https://www.avidbio.com

Analyst Forecast

According to 3 analyst ratings, the average rating for CDMO stock is "Hold." The 12-month stock price forecast is $12.25, which is a decrease of -1.41% from the latest price.

Buy 33.33%

Hold 66.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Avid Bioservices Inc. is scheduled to release its earnings on Apr 23, 2025, after market closes.
Analysts project revenue of $42.28M, reflecting a 24.35% YoY growth and earnings per share of -0.03, making a -62.50% decrease YoY.

Why Price Moved

2 months ago · Source

+11.48%

Avid Biosciences shares are trading higher after t... Unlock content with Pro Subscription

4 months ago · Source

+17.21%

Avid Bioservices shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results. Also, RBC Capital maintained an Outperform rating on the stock and raised its price target from $8 to $12.

News

1 week ago · businesswire.com

AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avid Bioservices...

2 weeks ago · businesswire.com

CDMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avid Bioservices, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to funds managed by GHO Capital Partners LLP and Am...

1 month ago · businesswire.com

CDMO Investors Have the Opportunity to Join Investigation of Avid Bioservices, Inc. with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--CDMO Investors Have the Opportunity to Join Investigation of Avid Bioservices, Inc. with the Schall Law Firm.

1 month ago · seekingalpha.com

Lifecore Biomedical: An Interesting CDMO Pure Play

Lifecore, a leading CDMO, specializes in sterile injectable pharmaceuticals and is poised to benefit from the growing CDMO market and potential GLP-1 opportunities. The company is doubling production ...

2 months ago · businesswire.com

Punch and Associates sends letter to Board of Directors of Avid Bioservices, Inc.

MINNEAPOLIS--(BUSINESS WIRE)--Punch & Associates intends to vote AGAINST proposed acquisition of Avid Bioservices, Inc. by GHO Capital and Ampersand Capital.

2 months ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Avid Bioservices, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Avid (NASDAQ: CDMO) for possible breaches of fiduciary duty and other violations of law in its transaction with GHO and Ampersand. Click here to ...

2 months ago · reuters.com

Avid Bioservices to be acquired by GHO and Ampersand for about $1.1 bln

Avid Bioservices said on Wednesday that it has agreed to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion.